Physician profile
Michael A Gordon
NPI 1356306807
$3,765.91
in general payments reported to CMS, 2019-2025
22 companies · $482 in 2025
The $482 reported for 2025 was more than what a typical Otolaryngology provider received nationally (typical 2025 total: $317).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $156 · 2020: $141 · 2021: $510 · 2022: $969 · 2023: $836 · 2024: $671 · 2025: $482.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,989.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,989.31 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Alphatec Spine, INC | $943.10 | 2021-2022 | |
| Regeneron Healthcare Solutions, INC. | $708.37 | 2019-2025 | Dupixent |
| Glaxosmithkline, LLC. | $543.13 | 2021-2025 | Nucala |
| Optinose US, INC. | $366.75 | 2019-2025 | |
| Abbvie INC. | $233.60 | 2022-2024 | |
| Inspire Medical Systems, INC. | $188.15 | 2023-2025 | Inspire |
| Genzyme Corporation | $157.49 | 2021-2025 | |
| Kaleo, INC. | $117.03 | 2023-2024 | Auvi-Q |
| Takeda Pharmaceuticals U.S.A., INC. | $86.84 | 2021-2025 | Cuvitru |
| Novartis Pharmaceuticals Corporation | $76.84 | 2019-2025 | |
| Genentech USA, INC. | $63.36 | 2024-2025 | Xolair |
| Alk-Abello, INC | $52.00 | 2020-2022 | |
| Amgen INC. | $50.65 | 2023-2024 | Tezspire |
| Grifols USA, LLC | $39.65 | 2022-2025 | Xembify |
| Smith+Nephew, INC. | $27.99 | 2019-2024 |
Show all 22 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Phadia US INC. | $21.21 | 2023 | Immunocap |
| Merck Sharp & Dohme LLC | $19.70 | 2021 | |
| Eyevance Pharmaceuticals LLC | $15.99 | 2020 | |
| Hikma Pharmaceuticals USA | $15.14 | 2022 | |
| Dermavant Sciences, INC. | $14.35 | 2024 | Vtama |
| Sun Pharmaceutical Industries INC. | $13.45 | 2022 | |
| Mylan Pharmaceuticals INC. | $11.12 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Michael Gordon listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.